Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Vrije Universiteit Brussel manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 7 distinct examiners and 6 distinct art units. This degree of fragmentation means that almost every pending matter is being reviewed by a different official in a different administrative unit. The presence of 6 distinct art units indicates that the portfolio touches upon several specialized sub-sectors within the broader biotechnology field.
The busiest examiner for this portfolio is SAMALA, JAGADISHWAR RAO, who is responsible for 1 pending office action. This 1 action is the maximum workload for any individual examiner within the current set of 7 pending actions. The relationship between the actions and the 7 distinct examiners indicates a diversified prosecution landscape. Because each of the actions is assigned to a different examiner, the company must navigate unique individual examination styles simultaneously. This distribution suggests that the prosecution outcomes for this portfolio are decentralized across the patent office's personnel.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 1 | 68.0% | +55.6% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 67d overdue |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 67d overdue |
| 18269380 | IMMUNE CHECKPOINTS | BORGEEST, CHRISTINA M | 4d overdue |
| 18697218 | Fluorescently Labeled Immunoglobulin Single Variable Domains | SAMALA, JAGADISHWAR RAO | — |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | — |
| 17812951 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof | MARVICH, MARIA | — |
| 17604559 | MRNA FORMULATION | HOPKINS, SAMANTHA LAKE | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1634 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697218 | Fluorescently Labeled Immunoglobulin Single Variable Domains | SAMALA, JAGADISHWAR RAO | — | §103 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 1613 | §101§103§112 | Final Rejection | 67d overdue | Pending | Feb 29, 2024 |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | 1674 | §102§112Other | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18269380 | IMMUNE CHECKPOINTS | BORGEEST, CHRISTINA M | 1675 | §112 | Final Rejection | 4d overdue | Pending | Jun 23, 2023 |
| 17812951 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | — | Pending | Jul 15, 2022 |
| 17604559 | MRNA FORMULATION | HOPKINS, SAMANTHA LAKE | 1641 | §103DP | Final Rejection | — | Pending | Oct 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial